Peter JH Scott, PhD

 Peter J. Scott
Paul L Carson Ph.D. Legacy Professor of Radiology
Associate Chair, Basic Science Research
Program Assistant, Cyclotron Facility
Department of Radiology
Professor of Pharmacology
Medical School
Professor of Medicinal Chemistry
College of Pharmacy
Email:
[email protected]
Available to mentor
Peter JH Scott, PhD
Peter J. Scott
Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • Qualifications
    • PhD
      University of Durham, Durham, United Kingdom
      2001 - 2005
    • BSc
      Loughborough University, Loughborough, Leicestershire,, United Kingdom
      1997 - 2001

    Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      Biosciences Initiative

    Research Overview

    - Developing new methods for radiolabeling bioactive molecules.
    - Design and synthesis of new radiotracers for PET imaging of CNS disorders such as Alzheimer's disease.
    - cGMP radiopharmaceutical manufacture.
    - Implementation of new technology for radiochemistry and PET imaging, including automation, artificial intelligence and the internet of things.
    .

    Recent Publications

     See All Publications
    • Journal Article
      Highlight selection of radiochemistry and radiopharmacy developments by editorial board
      Kiss OC, Penuelas I, Rey A, Yang Z, Gillings N, Pillai A, Cazzola E, Reilly RM, Taddei C, Liu J, van Dam M, Furumoto S, Zhang J, Bernardes ES, Lodi F, Deuther-Conrad W, Huang YY, Lagebo YJ, Ekoume FP, Avila-Rodriguez MA, Summers B, Elrefaei A, Salgueiro M, Ramogida CF, Scott PJH. Ejnmmi Radiopharmacy and Chemistry, 2026 Dec 1; 11 (1): DOI:10.1186/s41181-026-00443-1
    • Journal Article
      Functionalization of indoles using a DABCO-Meldrum's acid reagent
      Allen AC, Kim H, Hubers D, Kim I, Han G, Scott PJH, Witek JA. Tetrahedron Letters, 2026 Sep 1; 182: DOI:10.1016/j.tetlet.2026.156154
    • Journal Article
      Assessment of PET drug adverse events in the U.S. since the implementation of 21 CFR part 212
      Dakanali M, VanBrocklin HF, Zigler SS, Scott PJH. EJNMMI Radiopharmacy and Chemistry, 2026 Jul 24; DOI:10.1186/s41181-026-00482-8
    • Journal Article
      Automated radiosynthesis and biodistribution of [18F]fluoroflutamide
      Kaup G, Witek JA, Cingoranelli SJ, Stauff J, Raffel D, Brooks AF, Scott PJH, Wright JS. EJNMMI Radiopharmacy and Chemistry, 2026 Jul 24; DOI:10.1186/s41181-026-00453-z
    • Journal Article
      Current Status of Clinical 177Lu-PSMA Radiopharmaceutical Therapies: Insights from a Survey of High-End Nuclear Medicine Theranostic Centers.
      Djekidel M, Dominguez-Konicki L, Osman M, Scott PJH, Berenji GR. J Nucl Med Technol, 2026 Jul 21; DOI:10.2967/jnmt.126.272466
      PMID: 42481177
    • Journal Article
      18F-labelling of (hetero)aryl halides via sequential Miyaura borylation/copper-mediated radiofluorination
      Noel AN, Greco SG, Horikawa M, Spiller TE, Nichols DL, Witek JA, Brooks AF, Scott PJH, Sanford MS. Chemical Science, 2026 Jul 1; 17 (25): 12358 - 12364. DOI:10.1039/d6sc01625a
    • Journal Article
      Imaging Primary Chronic Pain Syndromes: Current Evidence, Clinical Relevance, and Advances in MRI and PET/CT
      Ora M, Cai Y, Bathla G, Agarwal A, Gupta V, Scott PJH, Soni N. Seminars in Roentgenology, 2026 Jul 1; 63: DOI:10.1016/j.ro.2026.151004
      PMID: 42217291
    • Journal Article
      NMB innovators series. Professor Michael R. Kilbourn, PhD: An enduring legacy of mentorship, scientific curiosity and research excellence
      Scott PJH. Nuclear Medicine and Biology, 2026 Jul 1; 158-159: DOI:10.1016/j.nucmedbio.2026.109660
      PMID: 42531856

    Featured News & Stories
    Department News

    Atonco and University of Michigan Announce Collaboration on Phase 1-2a Clinical Study of ATO-101™

    Bladder cancer ranks among the most common cancers, with limited success from current therapies like BCG. Atonco’s ATO-101™, a targeted radiopharmaceutical using astatine-211, will be tested in a Phase 1–2a trial led by Drs. Viglianti and Scott to assess its precision and safety. This study represents a promising step toward more effective, less invasive treatments for bladder cancer.
    Department News

    Faculty Promotions (effective September 1, 2023)

    Faculty Promotions (effective September 1, 2023) at the U-M Medical School Department of Pharmacology